Dr. Djaballah has several years of industrial experience in early drug discovery gained over the years in pharma and biotech companies. He has extensive experiences in the areas of fluorescence technology, assay development, automation/robotics, HTS, compound & screening data management, software development & novel technologies. Dr Djaballah has been involved in developing and screening several targets in various therapeutic areas, including antibacterials, antivirals, antifungals, diabetes, CNS, cardiovascular, oncology & inflammation. He is currently the director of the high throughput drug screening core facility at Memorial Sloan Kettering Cancer Centre in New York. He obtained his BSc (Hons.) in biochemistry and biotechnology from the University of Birmingham, and his PhD in biochemistry from the University of Leicester, both in England.
Illuminating Cellular Pathways through Combining High Content Assays with the BDA Method: Too Much Hay and Very Few Needles in Random RNAi Screening Stacks
Developing the appropriate and sensitive cell based assay together with the choice of methodology for hit nomination in random RNAi screening remain the main challenges as well as pitfalls for the technology. Automated microscopy-based assays offer the provision and availability of an image allowing visual inspection for acceptance or complete rejection of a perturbed phenotype caused by a given RNAi molecule in an arrayed screen.
Add to Calendar ▼2013-06-06 00:00:002013-06-07 00:00:00Europe/LondonEuropean Lab Automation 2013European Lab Automation 2013 in HamburgHamburgSELECTBIOenquiries@selectbiosciences.com